Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis  
2/17/2014 8:46:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MECHELEN, Belgium, Feb. 17, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that patient recruitment has been completed for the clinical Proof of Concept study with GLPG0974. GLPG0974 presents a novel mode of action for the treatment of ulcerative colitis, a debilitating inflammatory bowel disease. T he efficacy and safety of GLPG0974 are being evaluated during a 28-day treatment period. Topline results from this study are expected in June 2014. GLPG0974 is fully proprietary to Galapagos.

Help employers find you! Check out all the jobs and post your resume.